These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 21822304)
21. SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma. Evans L; Chen L; Milazzo G; Gherardi S; Perini G; Willmore E; Newell DR; Tweddle DA Cancer Lett; 2015 Jul; 363(1):37-45. PubMed ID: 25843293 [TBL] [Abstract][Full Text] [Related]
22. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771 [TBL] [Abstract][Full Text] [Related]
23. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931 [TBL] [Abstract][Full Text] [Related]
24. NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas. Suenaga Y; Islam SM; Alagu J; Kaneko Y; Kato M; Tanaka Y; Kawana H; Hossain S; Matsumoto D; Yamamoto M; Shoji W; Itami M; Shibata T; Nakamura Y; Ohira M; Haraguchi S; Takatori A; Nakagawara A PLoS Genet; 2014 Jan; 10(1):e1003996. PubMed ID: 24391509 [TBL] [Abstract][Full Text] [Related]
25. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma. Gupta A; Williams BR; Hanash SM; Rawwas J Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187 [TBL] [Abstract][Full Text] [Related]
26. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells. Veschi V; Petroni M; Cardinali B; Dominici C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Giannini G PLoS One; 2012; 7(11):e49139. PubMed ID: 23152863 [TBL] [Abstract][Full Text] [Related]
27. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123 [TBL] [Abstract][Full Text] [Related]
28. A cell-based high-throughput screen addressing 3'UTR-dependent regulation of the MYCN gene. Sidarovich V; Adami V; Quattrone A Mol Biotechnol; 2014 Jul; 56(7):631-43. PubMed ID: 24515800 [TBL] [Abstract][Full Text] [Related]
29. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Molenaar JJ; Ebus ME; Geerts D; Koster J; Lamers F; Valentijn LJ; Westerhout EM; Versteeg R; Caron HN Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12968-73. PubMed ID: 19525400 [TBL] [Abstract][Full Text] [Related]
30. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746 [TBL] [Abstract][Full Text] [Related]
31. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma. Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575 [TBL] [Abstract][Full Text] [Related]
32. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line. Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372 [TBL] [Abstract][Full Text] [Related]
33. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation. Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814 [TBL] [Abstract][Full Text] [Related]
34. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764 [TBL] [Abstract][Full Text] [Related]
35. Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology. Schwab M Ann N Y Acad Sci; 2002 Jun; 963():63-73. PubMed ID: 12095930 [TBL] [Abstract][Full Text] [Related]
37. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555 [TBL] [Abstract][Full Text] [Related]